Moderna’s mRNA flu vaccine more effective than standard shot in late-stage trial
Moderna's mRNA flu vaccine was found to be 27% more effective than standard flu shots in a late-stage trial involving over 40,000 adults. The trial results showed that 2% of the mRNA vaccine group got sick, compared to 2.8% in the standard flu shot group.
Moderna's mRNA flu vaccine outperformed standard flu shots in a Phase 3 clinical trial. The trial involved over 40,000 adults aged 50 and above across 301 sites in 11 countries. The mRNA vaccine group had a lower incidence of illness, with 2% getting sick compared to 2.8% in the standard flu shot group. Side effects were mild and short-lived. The FDA had previously rejected Moderna's original submission, but the new results could bolster the vaccine's chances of approval. The mRNA technology allows for faster development and potentially better matching of the vaccine to emerging strains.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.